Skip to content
The BCI Briefing

Company profileCore BCI

JiMED

Japan's wireless implantable BMI, developed toward a first company-sponsored trial in people with ALS.

Location
Osaka, Japan
Founded
2020
Class
Core BCI
Also known as
JiMED Inc. · wiBMI
Sources last checked
4 Oct 2026

What they are building

Osaka company developing a fully implanted wireless brain-machine interface for people in a locked-in state.

Interface category
Electrocorticography
Signal
Local field potentials, including high-gamma activity
Invasiveness
Invasive
Recording / stimulation
Recording
Main use cases
Communicate, Control
Works with
Osaka University

Where they are clinically

Preclinical

Bench, animal or cadaver work. No human participants.

A company-sponsored clinical trial in people with ALS is in preparation; the wireless system has not yet been implanted in a registered trial.

Access today

Preclinical

Not yet tested in people.

Shown in people
No implant in a registered trial yet.
Still an aim
A company-sponsored trial of a wireless implant for people with ALS, which its Series B of ¥330 million is meant to start.
What stands in the way
Capital and time: the round is about $2 million, against rounds of hundreds of millions elsewhere.

On record here: 0 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

JiMED is the main Japanese programme for an implanted communication BCI and carries a long academic record of ECoG research into a company. Its funding is small by US or Chinese standards, which makes it a useful marker of how far public grants and a modest venture round can take an implant in Japan's regulatory system.

Key milestones

  1. 2026

    Series B of ¥330 million reported, led by Keio Innovation Initiative, to fund the start of the ALS trial.

    Dealroom

  2. 2020

Funding history

  • 2026$2.2MSeries B · led by Keio Innovation InitiativeReported as JPY 330 million. Converted by the Briefing at about 150 yen to the dollar; the source gives no dollar figure.Reported by a deal database that we have not opened; month not recorded.

Investors namedKeio Innovation Initiative

Rounds in the Briefing’s sample only; not a complete funding history.

Leadership

  • Masayuki Hirata

    Founder and CEO

As publicly stated by the organisation. Not a complete list.

IP and patents

3
patent families identified and counted as BCI
2016
earliest first filing among them
2
first filed since 2021; the latest years are incomplete
3 of 3
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: neural decoding (3), electrodes and arrays (1), signal acquisition (1), signal processing (1). A family can carry several.

Published in: Japan (3), United States (1), counted over the 3 families whose full record was read.

Representative families

Families found for JiMED in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Sources

  1. 01

    JiMED Inc. — NEDO deep-tech startup profile (opens in a new tab)

    Independent reportingNEDO (New Energy and Industrial Technology Development Organization, Japan)Checked against source 4 Oct 2026

    Profile by the Japanese government agency that funds the company. Gives the founding year, the chief executive and the trial plan.

  2. 02

    JiMED raises ¥330M Series B led by Keio Innovation Initiative for wireless implantable BCI (opens in a new tab)

    Independent reportingDealroomSource identified, not opened

    Identified through search; not opened.